Xeljanz Partial Change Approval
Tofacitinib citrate
Approval Information
Brand NameXeljanz
Partial Change Approval
Generic NameTofacitinib citrate
ApprovedMay 2018
TypeInitial Approval
Review Reports
Want structured data, translation summaries & alerts?
PharmaLens is building the most comprehensive English-language PMDA intelligence platform. Join the waitlist for early access.
Join the WaitlistSource: PMDA Website. Review reports are provided under Japan's Public Data License v1.0. Translations and structured data by PharmaLens are unofficial and for reference only.